Economic evaluation of dapagliflozin versus metformin in Chinese patients whose diabetes is inadequately controlled with diet and exercise

Table 1 Clinical parameters used in the model

Parameters	Metformin (versus placebo)		Dapagliflozin (versus placebo)		Source^a
Parameters	Expected value	Range	Expected value	Range	Source^a
Decrease in HbA1c	1.13	0.9–1.37	0.50	0.21–0.78	[20]
Decrease in SBP (mmHg)	2.00	− 7.26 to 11.21	8.11	1.48–14.74	[12,13,14]
Decrease in total-C (mg/dL)	11.93	− 0.79 to 24.07	2.80	− 5.92 to 11.63	[12,13,14]
Increase in HDL-C (mg/dL)	2.01	− 7.67 to 11.53	8.10	1.24–15.14	[12,13,14]

HbA1c glycosylated hemoglobin, HDL-C high-density lipoprotein cholesterol, SBP systolic blood pressure
^aThe reported data from trials were synthesized by using network meta-analysis

ISSN: 1478-7547